Find Clinical Trials

Search thousands of clinical trials by condition, location, and eligibility criteria

0
Total Trials
0
Trials Recruiting
0
Conditions Covered
0
Locations Worldwide
0
Sponsors
Clinical trial guides

Browse trials by condition

View all guides

Browse by location

Showing 12 of 4229 trials
Conditions Heredo Familial Tumors, Psycho Oncologic...
Phase Not Applicable
Enrollment 100
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-19
Study Details Design, interventions, and primary outcomes

About This Study

This is a descriptive, exploratory cross-sectional, single-center national study. The study asks a sample of women carrying pathogenic variants associated with hereditary breast and ovarian cancer who have undergone risk-reducing mastectomy (MRR) and have signed informed consent to complete an interview developed on the REDCap platform and sent to their personal email address. The aim of the study is to investigate patients' experiences of satisfaction and their correlations with variables included in the survey, based on evidence from the scientific literature. These variables include aspects derived from the literature and clinical practice, such as: motivations for choosing to undergo MRR, type of surgical procedure performed, type of reconstruction, presence of residual sensitivity, possible postoperative complications, and the number of surgical procedures required to achieve the final outcome; stability of the couple relationship, partner support, impact of surgery on sexuality, the key question regarding the decision to undergo MRR (question no. 11), and whether the participant would recommend the same pathway to others. In addition, the survey includes items derived from the Body Image Scale (Hopwood et al., 2001), translated and validated in Italian (Italian version: Cheli et al., 2016), appropriately adapted to assess the same variable in relation to the MRR procedure (questions no. 2, 4, 6, and 8). Finally, the last section of the survey includes administration of the 12-Item Short Form Survey (SF-12), a widely used measure of quality of life. The questionnaires included in the survey will be appropriately indicated.

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Primary Outcomes

  • Patient satisfaction following risk-reducing mastectomy (MRR). (Up to December 2026)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2025-05-01
Completion: 2026-12
Eligibility
Age: 25 Years – 70 Years
Sex: FEMALE
Volunteers: false
Enrollment: 100 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Fondazione IRCCS Policlinico San Matteo di Pavia
Contact Information
Study Contact:
Francesca Dionigi, Psychology
0039 0382501760
f.dionigi@smatteo.pv.it
Fondazione IRCCS Policlinico San Matteo di Pavia
Interventions
N/A
Study Locations (1 sites)
Fondazione IRCCS Policlinico San Matteo di Pavia, Pavia, Pavia 27100 Italy
Eligibility Criteria
* Female patients aged 18 years or older. * Carriers of pathogenic variants associated with hereditary breast and ovarian cancer syndromes (e.g., BRCA1, BRCA2, or other clinically relevant variants). * Having previously undergone risk-reducing mastectomy (MRR). * Being followed or previously evaluated at the clinical center participating in the study. * Ability to understand the study information and complete the survey. * Provision of written informed consent for participation in the study. * Inability to understand or complete the questionnaire. * Refusal or inability to provide informed consent. * Incomplete or missing responses to the survey preventing adequate evaluation of the study outcomes.
Conditions Breast Cancer Screening, Colon Cancer Sc...
Phase NA
Enrollment 820
Locations 2 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-19
Study Details Design, interventions, and primary outcomes

About This Study

The goal of this study is to test bundled familial cancer risk assessment + multicancer (colorectal + breast) vs. single (breast) cancer navigation, using a wait list control for colorectal cancer screening referral and navigation. Among those eligible, this study will test usual care referral to genetic services vs. pretest education + usual care referral. The study also will assess how bundled multicancer navigation works and for whom it is most effective through a multisite, mixed-methods patient- and organization-level process evaluation.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Screening Masking/blinding: None

Interventions / Regimen

  • Behavioral: Breast cancer screening navigation — Single cancer navigation includes the following, oriented to breast cancer only: cancer education, barrier assessment and resolution, screening exam scheduling, text and mail reminders, documentation of appointment completion and results communicated to patient.
  • Behavioral: Multicancer screening navigation — Multi-cancer navigation includes the following, oriented to breast and colorectal cancers: cancer education, barrier assessment and resolution, screening exam scheduling, text and mail reminders, documentation of appointment completion and results communicated to patient.
  • Behavioral: Usual care genetics referral — Referral for genetics will be provided at the completion of the navigation call.
  • Behavioral: Pretest education + usual care genetics referral — Print education regarding the genetic counseling and testing process and specific tips to support at-home testing. Referral for genetics will be provided at the completion of the navigation call.

Primary Outcomes

  • Receipt of colorectal cancer screening (6 months after navigation completion)
  • Receipt of breast cancer screening (Six months after completion of navigation)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2026-05-06
Completion: 2029-05-31
Eligibility
Age: 45 Years – 74 Years
Sex: FEMALE
Volunteers: true
Enrollment: 820 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Georgetown University
Collaborators: National Cancer Institute (NCI)
Contact Information
Study Contact:
Suzanne O'Neill, PhD
202-687-0869
sco4@georgetown.edu
Chiranjeev Dash, PhD
202-687-1542
cd422@georgetown.edu
Scott Siegel, PhD
SSiegel@christianacare.org
ChristianaCare-Helen F. Graham Cancer Center & Research Institute
Interventions
  • Behavioral: Breast cancer screening navigation — Single cancer navigation includes the following, oriented to breast cancer only: cancer education, barrier assessment and resolution, screening exam scheduling, text and mail reminders, documentation of appointment completion and results communicated to patient.
  • Behavioral: Multicancer screening navigation — Multi-cancer navigation includes the following, oriented to breast and colorectal cancers: cancer education, barrier assessment and resolution, screening exam scheduling, text and mail reminders, documentation of appointment completion and results communicated to patient.
  • Behavioral: Usual care genetics referral — Referral for genetics will be provided at the completion of the navigation call.
  • Behavioral: Pretest education + usual care genetics referral — Print education regarding the genetic counseling and testing process and specific tips to support at-home testing. Referral for genetics will be provided at the completion of the navigation call.
Study Locations (2 sites)
ChristianaCare-Helen F. Graham Cancer Center & Research Institute, Newark, Delaware 19713 United States
Georgetown University, Washington D.C., District of Columbia 20007 United States
Eligibility Criteria
Inclusion Criteria: 1. Seeking screening navigation services through programs at a participating site (Georgetown Lombardi Cancer Center or Helen F. Graham Cancer Center \& Research Institutes) 2. Eligible for breast cancer screening while also due and eligible for colorectal cancer screening (per USPSTF guidelines) 3. Female sex 4. Aged 45-74 5. Identify as Black/African American race and/or Hispanic/Latin(e)(a) ethnicity 6. Speak English or Spanish with enough fluency to complete study activities 7. Stated willingness to comply with all study procedures (navigation, surveys) and availability for the duration of the study 8. Provision of completed electronic informed consent form Exclusion Criteria: 1. Not engaged with or planning to use navigation programs at Georgetown Lombardi Cancer Center and Helen F. Graham Cancer Center \& Research Institute 2. Not eligible for breast cancer screening or not due and eligible for colorectal cancer screening (per USPSTF guidelines) 3. History of breast and/or colorectal cancer; or Reporting symptoms related to breast and/or colorectal cancer (e.g., GI bleeding, breast mass) 4. Male sex, Intersex, or other sex 5. Under age 45 or over age 74 6. Identifies as neither Black/African American race nor Hispanic/Latin(e)(a) ethnicity 7. Speaks neither English nor Spanish with enough fluency to complete study activities 8. Stated unwillingness to comply with study procedures (navigation, surveys) or unavailability for the duration of the study 9. Inability to provide electronic informed consent, or needing another person to authorize informed consent on their behalf
Conditions Breast Cancer, Reconstructive Surgery, B...
Phase Not Applicable
Enrollment 350
Locations 8 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-19
Study Details Design, interventions, and primary outcomes

About This Study

A multicentre prospective cohort study will monitor the efficacy and safety of Autologous Fat Transfer (AFT) with pre-expansion. AFT will be evaluated in terms of quality of life, aesthetic result, complications, oncological safety and cost-effectiveness. It follows the BREAST trial, the randomised controlled trial comparing AFT with implant-based reconstruction. In this study, patients all receive AFT.

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Interventions / Regimen

  • Procedure: Autologous Fat Transfer — Female breast cancer patients who were surgically treated with mastectomy could opt for a full breast reconstruction with Autologous Fat Transfer in combination with external expansion.

Primary Outcomes

  • Breast-related Quality of life (2 years)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2020-12-09
Completion: 2026-10
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 350 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Maastricht University Medical Center
Collaborators: ZonMw: The Netherlands Organisation for Health Research and Development
Principal Investigators:
  • Andrzej Piatkowski de Grzymala, MD, MSc (PRINCIPAL_INVESTIGATOR) - Maastricht University Medical Center
Contact Information
Study Contact:
Jamilla Wederfoort, MD, MSc
0031-(0)43 387 2308
sander.schop@mumc.nl
An Deliaert, MD, MsC
Viecuri Venlo
Ute Schmidbauer, MD, MsC
Ziekenhuis groep Twente (ZGT)
Interventions
  • Procedure: Autologous Fat Transfer — Female breast cancer patients who were surgically treated with mastectomy could opt for a full breast reconstruction with Autologous Fat Transfer in combination with external expansion.
Study Locations (8 sites)
Maastricht University Medical Center+, Maastricht, Limburg 6229 HX Netherlands
Viecuri Venlo, Venlo, Limburg Netherlands
Amsterdam University Medical Center (VUMC), Amsterdam, Netherlands
Rijnstate, Arnhem, Netherlands
Alexander Monro, Bilthoven, Bilthoven, Netherlands
Amphia, Breda, Netherlands
Ziekenhuis groep Twente (ZGT), Hengelo, Netherlands
Medical Center Leeuwarden, Leeuwarden, Netherlands
Eligibility Criteria
Inclusion Criteria: * Female gender * Age of 18 years and older * History or in candidate for a mastectomy procedure in the near future * Patients undergoing preventive mastectomy * Patients' choice to undergo a breast reconstruction * Wanting to participate in this study * Patient is able to wear the external expansion device Exclusion Criteria: * Active smoker or a history of smoking 4 weeks prior to surgery * Current substance abuse * History of lidocaine allergy * History of silicone allergy * 4 weeks or less after chemotherapy * History of radiation therapy in the breast region * Oncological treatment includes radiotherapy after mastectomy * Kidney disease * Steroid dependent asthma (daily or weekly) or other diseases * Immune-suppressed or compromised disease * Uncontrolled diabetes * BMI\>30 * Large breast size (i.e. larger than cup C), unless the patient prefers reduction of the contralateral side towards Cup C * Extra-capsular silicone leaking from the encapsulated implant from a previous breast reconstruction * The treating plastic surgeon has strong doubts on the patient's treatment compliance
Conditions Breast Cancer, Advanced Breast Cancer
Phase PHASE2
Enrollment 265
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-19
Study Details Design, interventions, and primary outcomes

About This Study

This is a randomized, controlled, open-label, phase II study to explore the efficacy and safety of Everolimus in combination with standard first-line endocrine therapy for the HR+/ HER2-SNF1 subtype of advanced breast cancer. The study was used to explore the efficacy of Everolimus in combination with standard endocrine therapy.

Design

Study type: Interventional Phases: Phase2 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: Everolimus 10 mg — Everolimus is a kind of mTOR inhibitor which has been approved to use in several kinds of cancers, especially in metastatic breast cancer.
  • Drug: CDK4/6 Inhibitor SHR6390 — Dalpiciclib (SHR6390) is a kind of CDK4/6 inhibitor that has demonstrated tolerability and preliminary clinical activity in patients with heavily pretreated hormone receptor-positive, HER2-negative advanced breast cancer.
  • Drug: Aromatase inhibitor and Fulvestrant combined with CDK4/6 inhibitors — Endocrine therapy combined with CDK4/6 inhibitors is the standard first-line therapy for advanced luminal breast cancer. Investigators choose endocrine therapy including Letrozole, Anastrozole, Exemestane, and Fulvestrant. Postmenopausal participants should use Goserelin.

Primary Outcomes

  • Progression Free Survival (PFS) (Approximately 5 years)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2
Status: Recruiting
Start Date: 2023-07-26
Completion: 2028-01
Eligibility
Age: 18 Years – 75 Years
Sex: FEMALE
Volunteers: false
Enrollment: 265 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Fudan University
Principal Investigators:
  • Zhimin Shao, MD,PhD (PRINCIPAL_INVESTIGATOR) - Fudan University
Contact Information
Study Contact:
Zhimin Shao, MD, PhD
+86-021-64175590
zhimingshao@yahoo.com
Min He, MD, PhD
+86-021-64175590
min1.he@shca.org.cn
Zhimin Shao Shao, MD,PhD
86-021-64175590
zhimingshao@yahoo.com
Fudan University Shanghai Cancer Center
Interventions
  • Drug: Everolimus 10 mg — Everolimus is a kind of mTOR inhibitor which has been approved to use in several kinds of cancers, especially in metastatic breast cancer.
  • Drug: CDK4/6 Inhibitor SHR6390 — Dalpiciclib (SHR6390) is a kind of CDK4/6 inhibitor that has demonstrated tolerability and preliminary clinical activity in patients with heavily pretreated hormone receptor-positive, HER2-negative advanced breast cancer.
  • Drug: Aromatase inhibitor and Fulvestrant combined with CDK4/6 inhibitors — Endocrine therapy combined with CDK4/6 inhibitors is the standard first-line therapy for advanced luminal breast cancer. Investigators choose endocrine therapy including Letrozole, Anastrozole, Exemestane, and Fulvestrant. Postmenopausal participants should use Goserelin.
Study Locations (1 sites)
Fudan University Shanghai Cancer Center, Shanghai, Shanghai Municipality 200032 China
Eligibility Criteria
Inclusion Criteria: * Patients need to meet all of the following conditions * Patients must be ≥18 and ≤ 75 years of age; * Pathologically confirmed breast cancer is HR+/HER2- breast cancer (IHC ER \>10%, or/and PR\>10%, HER 0 OR +, if HER2++, FISH negative); * SNF1 subtype definition: SNF1 subtype confirmed by digital pathology of H\&E sections; * Locally advanced breast cancer (radical local therapy is not possible) or metastatic breast cancer (without using adjuvant CDK4/6 inhibitors in the past, or one year after adjuvant CDK4/6 inhibitor therapy has ended); * No prior therapy (chemotherapy, targeted therapy, etc.) for advanced or metastatic breast cancer; * Patients with at least one measurable lesion that has not previously received radiation therapy and can be evaluated repeatedly according to RECIST 1.1; * The functions of the main organs are basically normal, and the following conditions are met: 1. Blood routine examination standards should meet: HB≥90g/L (no blood transfusion within 14 days); ANC≥1.5×109/L; PLT≥75×109/L; 2. Biochemical examination shall meet the following standards: TBIL≤1.5×ULN (upper limit of normal value); ALT and AST≤3 x ULN; In case of liver metastasis, ALT and AST≤5×ULN; Serum Cr ≤1.5×ULN, endogenous creatinine clearance \> 50ml/min (Cockcroft-Gault formula); * ECOG performance status 0 or 1; The expected survival is more than 3 months; * Fertile female is required to use a medically approved contraceptive during study treatment and for at least 3 months after the last use of the study drug; * Patients voluntarily join the study, sign the informed consent, have good compliance, and cooperate with follow-up. Exclusion Criteria: * Patients with any of the following conditions were excluded from the study * Patients with central nervous system metastasis out of control (symptoms need to use glucocorticoids or mannitol). * A history of clinically significant or uncontrolled heart disease, including congestive heart failure, angina pectoris, myocardial infarction within the last 6 months, or ventricular arrhythmia; * Radiotherapy, chemotherapy, surgery, other targeted therapy and immunotherapy for advanced HR+/HER2- breast cancer within 4 weeks prior to first administration of drugs used in this study. * Pregnant or lactating patients; * Other malignancies within the previous 3 years, excluding cured skin basal cell carcinoma and cervical carcinoma in situ; * Significant comorbid medical conditions, including mental illnesses that the investigator or sponsor believes would adversely affect the patient's participation in the study; * Allergic physique, or known allergic history of the drug components of this program; Or allergic to other monoclonal antibodies; * The investigator does not consider the patient suitable for participation in any other circumstances of the study.
Conditions Prostate Cancers, Breast Cancer, Head an...
Phase Not Applicable
Enrollment 850
Locations 5 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-19
Study Details Design, interventions, and primary outcomes

About This Study

This registry study aims to evaluate the effectiveness and clinical impact of specimen PET-CT imaging by analyzing the correlation between specimen PET-CT images, intraoperative interpretations, and histopathological findings. Additionally, it assesses how these imaging insights influence clinical decision-making and long-term patient outcomes. Through this comprehensive analysis in a real-world setting, the study seeks to generate valuable insights that can enhance specimen evaluation processes and ultimately improve patient care.

Design

Study type: Observational Observational model: Case Only Time perspective: Other

Primary Outcomes

  • To assess the correlation between the specimen PET-CT images and final histopathological examination of the specimen. (Perioperative)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2025-11-19
Completion: 2031-01-15
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 850 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: XEOS Medical
Contact Information
Study Contact:
Laurence Tack, Dr.
053 72 87 02
klinischestudies.secretariaat@azorg.be
AZORG
Filip Ameye, Dr.
+32 9 246 18 52
klinische.studies@mijnziekenhuis.be
AZ Maria Middelares
David Kersting, Dr.
+49 0201 723 0
info@uk-essen.de
Universitäts-klinikum Essen
Interventions
N/A
Study Locations (5 sites)
AZORG, Aalst, 9300 Belgium
AZ Maria Middelares, Ghent, Belgium
Universitäts-klinikum Essen, Essen, North Rhine-Westphalia 45147 Germany
UMCG, Groningen, Netherlands
University Hospitals Coventry and Warwickshire (UHCW) NHS Trust, Coventry, West Midlands CV2 2DX United Kingdom
Eligibility Criteria
Inclusion Criteria : All patients that were scheduled for resective surgery and for whom successful high-resolution PET-CT imaging was performed on their resected specimens using the AURA 10 PET-CT. Successful imaging means that the image contains at least a portion of the primary tumor, the radiotracer injection was correctly executed and there were no technical issues that lead to an uninterpretable PET-CT image. Or all patients that are scheduled for resective surgery and for whom high-resolution PET-CT imaging will be performed on their resected specimens using the AURA 10 PET-CT. Patients willing to provide informed consent for use of their relevant medical records. For retrospectively included patients with no further Long-Term Follow-Up (LTFU) data collection, a notification will be sent. Exclusion Criteria: * Under the age of 18 years at the time of resective surgery. * Women who are pregnant or breastfeeding.
Conditions Breast Cancer
Phase NA
Enrollment 1528
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-19
Study Details Design, interventions, and primary outcomes

About This Study

Several researches have proved that avoiding axillary surgery does not worsen the outcome of breast cancer patients with relatively low risk. Based on the routine axillary imaging evaluation (ultrasound and MR etc.) and latest dedicate lymph node PET (LymphPET), axillary nodal burden can be identified before operation. Therefore this prospective study are designed to evaluate the negative predictive value of LymphPET and to verify whether sentinel lymph node biopsy can be spared in patients with negative preoperative axillary assessment.

Design

Study type: Interventional Phases: Allocation: Intervention model: Single Group Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Procedure: SLNB is spared — SLNB is spared in patients with negative preoperative axillary assessment(including LymphPET and other imaging examinations)

Primary Outcomes

  • stage 1: negative predictive value (6 months)
  • stage 2: D-DFS(distant disease-free survival) (5 years)
  • stage 2: LRFS(local-regional free survival) (5 years)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2019-09-04
Completion: 2027-09-01
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 1528 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Fudan University
Principal Investigators:
  • Zhi-Min Shao (PRINCIPAL_INVESTIGATOR) - Fudan University
Contact Information
Study Contact:
Zhi-Min Shao
086-021-64175590
zhimingshao@yahoo.com
Zhiming Shao
+86-021-64175590
Fudan University Shanghai Cancer Center
Interventions
  • Procedure: SLNB is spared — SLNB is spared in patients with negative preoperative axillary assessment(including LymphPET and other imaging examinations)
Study Locations (1 sites)
Fudan University Shanghai Cancer Center, Shanghai, Shanghai Municipality 200032 China
Eligibility Criteria
Inclusion Criteria: stage 1: 1. female 2. ≥18 years old 3. invasive ductal carcinoma or DCIS proved by core needle biopsy 4. tumor size ≤ 5cm 5. negative preoperative axillary assessment(including body examination, ultrasound and MR examination) 6. patients is accessible for the following axillary surgery and pathological test(including sentinel lymph node biopsy and axillary lymph node dissection) stage 2: 1. female 2. ≥18 years old 3. invasive carcinoma proved by core needle biopsy 4. has plan for breast conserving surgery and adjuvant radiation after surgery 5. negative preoperative axillary assessment(including body examination, ultrasound and axillary PET mSUV\<0.27) 6. patients is accessible for the follow up Exclusion Criteria: stage 1: 1. distant metastases 2. in the procedure of neoadjuvant therapy 3. positive preoperative axillary assessment (including body examination, ultrasound and MR examination) 4. pregnancy or breastfeeding 5. axillary biopsy or axillary surgery before LymphPET 6. suffer from diabetes mellitus and without well control of bloodglucose 7. previous malignancy 8. allergic to tracer of LymphPET stage 2: 1. distant metastases 2. in the procedure of neoadjuvant therapy 3. positive preoperative axillary assessment (including body examination, ultrasound and PET mSUV≥0.27) 4. pregnancy or breastfeeding 5. axillary biopsy or axillary surgery before LymphPET 6. suffer from diabetes mellitus and without well control of bloodglucose 7. previous malignancy 8. allergic to tracer of LymphPET
Conditions Breast Cancer
Phase Not Applicable
Enrollment 78
Locations 12 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-19
Study Details Design, interventions, and primary outcomes

About This Study

The purpose of the study is to obtain and centralize data about cancer prevention strategies in women with a germline deleterious mutation in BRCA1-2 with or without a history of breast cancer in Italy

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Primary Outcomes

  • To obtain and centralize data about cancer prevention strategies in women with a germline deleterious mutation in BRCA1-2 with or without a history of breast cancer in Italy (10 years since enrolment)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2019-08-27
Completion: 2035-09-30
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 78 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Centro di Riferimento Oncologico - Aviano
Contact Information
Study Contact:
Fabio Puglisi, MD
0434 659310
fabio.puglisi@cro.it
Centro di Riferimento Oncologico - Aviano
Antonella Spada, MD
0434 659077
spadaa@cro.it
Centro di Riferimento Oncologico - Aviano
Lucia Del Mastro
0
lucia.delmastro@unige.it
IRCCS AOU San Martino, IST Genova
Interventions
N/A
Study Locations (12 sites)
Centro di Riferimento Oncologico - Aviano, Aviano, Pordenone 33081 Italy
IRCCS AOU San Martino, IST Genova, Genova, Italy
Azienda Ospedaliera Papardo, Messina, Italy
ASST Ovest Milanese, Milan, Italy
Azienda ospedaliera Universitaria di Modena, Modena, Italy
Università degli studi di Napoli Federico II, Naples, Italy
Azienda AUSL IRCCS - Reggio Emilia, Reggio Emilia, Italy
ASL Roma 1, Santo Spirito, Roma, Italy
IFO - Istituto Regina Elena (Oncologia medica 2), Roma, Italy
Policlinico Universitario Gemelli, Roma, Italy
Eligibility Criteria
Inclusion Criteria: Cohort A (Retrospective): 1. Female sex 2. Age ≥ 18 years 3. Signed informed consent 4. Documented germline deleterious mutation in BRCA1 and/or BRCA2 in people with: i) No history of cancer ii) Radically treated breast cancer iii) Stage IV breast cancer diagnosed after BRCA1-2 mutation detection 5. Admission to the participating Center since 1st of January 2010, prior to site activation Cohort B (Prospective): 1. Female sex 2. Age ≥ 18 years 3. Signed informed consent 4. Documented germline deleterious mutation in BRCA1 and/or BRCA2 in people with: i) No history of cancer ii) Radically treated breast cancer iii) Stage IV breast cancer diagnosed after BRCA1-2 mutation detection 5. Admission to the participating Center after site activation Exclusion Criteria: Cohort A/B (Retrospective/Prospective): 1\. Other malignancies diagnosed within five years prior to BRCA1-2 mutation detection, except for: * ovarian cancer stage I-II * basal or squamous cell carcinoma of the skin * melanoma in situ * CIS of the cervix

More Health Less Diabetes

NCT07079722
Recruiting
Conditions Pre-diabetes
Phase NA
Enrollment 90
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-19
Study Details Design, interventions, and primary outcomes

About This Study

The "More Health, Less Diabetes" project is a hybrid randomized controlled trial to prevent type 2 diabetes in individuals at risk through structured exercise and lifestyle education. While exercise benefits for people with diabetes are well-documented, evidence remains limited on the effectiveness and cost-effectiveness of in-person and home-based exercise programs in a prediabetic population. This study aims to understand the clinical and cost-effectiveness of a three-arm RCT (online, in-person, and a control group) in people at high risk of developing T2DM. This 12-month program includes six months of supervised exercise (3 times/week) and a six-month follow-up. During the first six months, both intervention groups will attend educational sessions to improve health literacy and promote healthy habits. The primary outcome will be 2h glycemia in an oral glucose tolerance test. Secondary outcomes include other aspects of glycemic control (HbA1c, fasting glycemia, HOMA-IR, Matsuda index), 24-hour movement, body composition, vascular health, physical fitness, and cost-effectiveness using a social return on investment approach.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Behavioral: Exercise — This project is a randomized controlled trial (RCT) with three distinct groups: a control group (CG), an online intervention group (OIG), and an in-person intervention group (IIG). The OIG will receive online educational sessions and structured home-based exercises, while the IIG will participate in in-person educational sessions and supervised physical exercise. The control group will not participate in educational sessions or structured physical exercise.

Primary Outcomes

  • 2-hour glucose tolerance test (OGTT) (1 year)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-09-01
Completion: 2026-12-20
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: true
Enrollment: 90 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Faculdade de Motricidade Humana
Contact Information
Study Contact:
João Magalhães Associate Professor, Doctor
967 832 539
joaomagalhaes@fmh.ulisboa.pt
João Magalhães Doctor, Doctor
(+351) 214 149 100
joaomagalhaes@fmh.ulisboa.pt
Faculty of Human Kinetics
Interventions
  • Behavioral: Exercise — This project is a randomized controlled trial (RCT) with three distinct groups: a control group (CG), an online intervention group (OIG), and an in-person intervention group (IIG). The OIG will receive online educational sessions and structured home-based exercises, while the IIG will participate in in-person educational sessions and supervised physical exercise. The control group will not participate in educational sessions or structured physical exercise.
Study Locations (1 sites)
Faculty of Human Kinetics, Lisbon, Lisbon District 1499-002 Portugal
Eligibility Criteria
Inclusion Criteria: 1. High or Very High Risk according to the FINDRISC questionnaire; 2. Analytical confirmation of no diagnostic criteria for Diabetes, following a type 2 Diabetes risk assessment; 3. Committed to making lifestyle changes to manage diabetes; 4. Internet access; 5. Availability to participate in the program as required (schedule, location); Exclusion Criteria: 1. pregnancy (self-report/medical record); 2. Inability to use digital devices 3. Presence of abnormalities on exercise stress test.
Conditions Metabolic Syndrome, Obesity, Sarcopenia,...
Phase Not Applicable
Enrollment 320
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-19
Study Details Design, interventions, and primary outcomes

About This Study

This study aims to evaluate the clinical value of multimodal ultrasound for assessing muscle mass in patients with metabolic diseases, including metabolic syndrome, type 2 diabetes, and simple obesity. Skeletal muscle is the largest metabolic organ in the human body and plays a critical role in glucose metabolism. Muscle mass reduction is common in patients with metabolic diseases and is associated with insulin resistance, poor disease control, and increased risk of complications. Currently available methods for muscle assessment, such as dual-energy X-ray absorptiometry (DXA), computed tomography (CT), and magnetic resonance imaging (MRI), have limitations including high cost, radiation exposure, or poor portability, making them unsuitable for routine bedside monitoring. Multimodal ultrasound combines B-mode imaging, shear-wave elastography, superb microvascular imaging, and artificial intelligence analysis to provide a comprehensive evaluation of muscle morphology, stiffness, microcirculation, and quality. This non-invasive, radiation-free, and portable technique may serve as an ideal tool for muscle assessment in clinical practice. This prospective observational study will enroll 320 participants divided into four groups: metabolic syndrome (n=80), type 2 diabetes (n=80), simple obesity (n=80), and healthy controls (n=80). All participants will undergo baseline assessments including clinical data collection, biochemical tests, muscle function tests (handgrip strength, gait speed, Short Physical Performance Battery \[SPPB\]), multimodal ultrasound examination (muscle thickness, cross-sectional area, echo intensity, shear wave velocity, Young's modulus, microvascular density), and DXA measurement as the reference standard. The three metabolic disease groups will be followed prospectively for 12 months with repeat assessments at 6 and 12 months. The primary objectives are to determine diagnostic thresholds of multimodal ultrasound parameters for detecting metabolic sarcopenia; to establish correlation between ultrasound parameters and metabolic indicators (blood glucose, glycated hemoglobin \[HbA1c\], homeostatic model assessment of insulin resistance \[HOMA-IR\], lipids); to develop a combined diagnostic model integrating ultrasound and clinical parameters; and to evaluate the predictive value of baseline ultrasound parameters for 12-month disease progression and complications. The findings will provide a non-invasive, convenient, and widely applicable tool for early screening, risk stratification, and therapeutic monitoring of muscle abnormalities in patients with metabolic diseases.

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Primary Outcomes

  • Area under the ROC curve (AUC) of multimodal ultrasound for detecting metabolic sarcopenia (At baseline assessment)
  • Sensitivity of multimodal ultrasound for detecting metabolic sarcopenia (At baseline assessment)
  • Specificity of multimodal ultrasound for detecting metabolic sarcopenia (At baseline assessment)
  • Positive predictive value of multimodal ultrasound for detecting metabolic sarcopenia (At baseline assessment)
  • Negative predictive value of multimodal ultrasound for detecting metabolic sarcopenia (At baseline assessment)
  • Correlation between ultrasound parameters and metabolic indicators (At baseline assessment)
  • Combined diagnostic model for metabolic sarcopenia (At baseline assessment)
  • Predictive value of baseline ultrasound for 12-month outcomes (12 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2023-07-01
Completion: 2027-12-31
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: true
Enrollment: 320 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Zhangzhou Municipal Hospital
Principal Investigators:
  • Wenting Jiang, Master's (PRINCIPAL_INVESTIGATOR) - Department of Ultrasound Medicine, Zhangzhou Hospital Affiliated to Fujian Medical University, China
Contact Information
Study Contact:
Fahui Lu, Master's
0596-2082027
18750745115@163.com
Wenting Jiang, Master's
13625926205
120722807@163.com
Fahui Lu, Master's
0596-2082027
18750745115@163.com
Zhangzhou Hospital, Fujian Medical University
Interventions
N/A
Study Locations (1 sites)
Zhangzhou Hospital, Fujian Medical University, Zhangzhou, Fujian 363000 China
Eligibility Criteria
Inclusion Criteria: * Diagnosis of metabolic syndrome according to the Chinese Consensus on Diagnosis and Management of Metabolic Syndrome (2020 edition), meeting at least 3 of the following 5 criteria: abdominal obesity, hypertension, hyperglycemia, hypertriglyceridemia, and low HDL-C. * Diagnosis of type 2 diabetes according to the ADA 2023 diagnostic criteria, with disease duration of at least 1 year. * Body mass index (BMI) \>= 28 kg/m², without hypertension, hyperglycemia, dyslipidemia, or other metabolic abnormalities. * Healthy volunteers without metabolic diseases, muscle diseases, chronic liver or kidney dysfunction, malignancies, cardiovascular diseases, or neurological disorders, and without long-term use of corticosteroids or other medications affecting muscle metabolism. * Age and sex matched across all four groups. * Willing and able to provide written informed consent and comply with all study procedures including ultrasound examination, DXA scan, and follow-up visits. Exclusion Criteria: * Severe hepatic or renal failure, malignancy, stroke, severe cardiovascular disease, or autoimmune diseases. * Long-term use of corticosteroids, muscle relaxants, or other medications affecting muscle metabolism. * Presence of movement disorders, joint diseases, muscle injury, muscular dystrophy, or other conditions affecting muscle function. * Pregnancy or lactation. * Inability to cooperate with ultrasound examination, DXA scanning, or follow-up assessments. * Any other condition that, in the opinion of the investigator, would interfere with the study objectives or participant safety.
Conditions PreDiabetes
Phase NA
Enrollment 80
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-19
Study Details Design, interventions, and primary outcomes

About This Study

Prediabetes is part of the natural history of type 2 diabetes mellitus, which is one of the main causes of morbidity and mortality in Mexico. It is known that overweight and obesity are the main risk factors for producing insulin resistance and this in turn leads to prediabetes-diabetes mellitus 2, acting alone or together, excess adipose tissue, mainly visceral, and Prediabetes increase cardiovascular risk before hyperglycemia occurs in the diagnostic criteria for diabetes. Effective strategies have been developed focused on changing lifestyle habits (changes in dietary patterns and increased physical activity) to promote weight loss in populations with and without glucose alterations present, but with limitations in the scope for the size of the affected population. There is a small number of studies developed for this purpose, focused on a multidisciplinary intervention in low- and middle-income countries. The prediabetes care program (PreCPro) is a care initiative developed by the primary care public health services of the Government of Mexico City (CDMX) to promote weight reduction and reduction of hyperglycemia through a intervention composed of an interdisciplinary care team, centered on the patient with a focus on promoting change in people's behavior to adopt healthy eating and physical activity habits. The target population of the prediabetes care program (PreCPro) is made up of patients with prediabetes, without advanced diseases, who receive regular care in public primary care services in Mexico City.

Design

Study type: Interventional Phases: Allocation: Intervention model: Single Group Primary purpose: Prevention Masking/blinding: None

Interventions / Regimen

  • Behavioral: Prediabetes Care Program — Patients are cared for by the medical, nutritionist and psychology team, in a total of 14 individual and group visits, during 12 months of care. The intervention has an initial stage lasting 6 months in which 12 visits will be scheduled and a transition stage lasting 6 more months in which 2 more visits will be scheduled. Patients will be evaluated at 6 months, 12 months and 24 months

Primary Outcomes

  • Glycemic control after the initial stage of the program (six months)
  • Change in weight after the initial stage of the program (six months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2023-03-01
Completion: 2027-03-01
Eligibility
Age: 18 Years – 70 Years
Sex: ALL
Volunteers: false
Enrollment: 80 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Clinica Especializada en el Manejo de la Diabetes en la Ciudad de Mexico
Principal Investigators:
  • Ruben Silva-Tinoco, MD (STUDY_DIRECTOR) - Clinica Especializada en el Manejo de la Diabetes
  • Viridiana De la Torre-Saldaña, MD (PRINCIPAL_INVESTIGATOR) - Clinica Especializada en el Manejo de la Diabetes
Contact Information
Study Contact:
Ruben Silva-Tinoco, MD
50381700
ruben_ost@hotmail.com
Viridiana De la Torre-Saldaña, MD
50381700
dradelatorreviridiana@gmail.com
Ruben Silva-Tinoco, MD
50381700
ruben_ost@hotmail.com
Clinica Especializada en el Manejo de la Diabetes
Interventions
  • Behavioral: Prediabetes Care Program — Patients are cared for by the medical, nutritionist and psychology team, in a total of 14 individual and group visits, during 12 months of care. The intervention has an initial stage lasting 6 months in which 12 visits will be scheduled and a transition stage lasting 6 more months in which 2 more visits will be scheduled. Patients will be evaluated at 6 months, 12 months and 24 months
Study Locations (1 sites)
Clinica Especializada en el Manejo de la Diabetes, Mexico City, Iztapalapa 09060 Mexico
Eligibility Criteria
Inclusion Criteria: * Having diagnosis of prediabetes * Acceptance for participation in the program by signing informed consent sheet Exclusion Criteria: * Any type of diabetes * Advanced diseases such as ischemic heart disease, heart failure, KDOQI renal failure ≥1, cerebral vascular disease with functional sequelae or those who have comorbidities that limit their life expectancy such as malignant tumors in advanced stages * Dependence of illicit drugs * Conditions that require short-term surgical treatment. * Pregnancy * Advanced cognitive deficit or serious psychiatric disorders that hinder treatment adherence * Use of medications whose use is associated with alterations in blood glucose levels or weight gain or loss, e.g. e.g. metformin, Glucagon-like peptide-1 receptor agonists, orlistat or corticosteroids * Actively taking any supplements dietary or under naturopathic, homeopathic or alternative therapies * Have any type of bariatric surgery procedure or weight loss device * Current participation in another lifestyle, behavior change, or weight loss or gain program or research study
Conditions Type 2 Diabetes Mellitus (T2DM), Obesity...
Phase NA
Enrollment 90
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-19
Study Details Design, interventions, and primary outcomes

About This Study

This study evaluates a new surgical device - the Metallic Anastomotic Clip (MAC) - for performing a laparoscopic bypass gastroenteroanastomosis with entero-enteric anastomosis (transit bipartition / "dual-path" procedure) in patients with type 2 diabetes mellitus (T2DM) who have overweight or Class I obesity (BMI 25-34.9 kg/m²). Currently, most bariatric and metabolic surgery procedures are only approved for patients with a BMI above 35 kg/m². However, many T2DM patients have BMI less 34.9 kg/m2 and cannot access surgical treatment under existing national guidelines. The transit bipartition procedure addresses this gap by creating a second food pathway from the stomach to the ileum while preserving normal duodenal digestion - producing a strong incretin (GLP-1) effect similar to GLP-1 receptor agonists (e.g., semaglutide), without causing excessive weight loss or requiring lifelong vitamin supplementation. The MAC is a novel compression anastomotic device designed to replace conventional hand-sewn or stapled anastomoses, potentially reducing complications such as anastomotic leak, bleeding, marginal ulcers, and strictures, while also lowering operative costs. Participants will be randomised into three groups. The study will assess metabolic outcomes (T2DM remission, glycaemic control), surgical safety, quality of life, and cost-effectiveness over a follow-up period of 2026-2027.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Procedure: Laparoscopic transit bipartition with Metallic Anastomotic Clip and Circular Fundocorporeal Gastroplication — The procedure begans creation circular fundocorporeal gastroplication without gastrectomy. A gastroplication calibrated over a 36F calibration tube using two layer nonabsorbable suture. The mobilisation of great curvature starts 4 cm above the pylorus and gastroplication starts 7 above the pylorus for the creation 3 cm gastro-ileal compression anastomosis using Metallic Anastomosis Clip (MAC) and leave a distance of 4 cm between the distal corner of the anastomosis and the pylorus. Laparoscopical the cecum and the last ileal loop are identified, and the bowel is retrogradely measured, from the ileocecal valve up to a 300 cm far from it, where the gastro-ileal anastomosis will be made. And than leave a distance of 50 cm from gastroileal anastomosis creation entero-enteric compression anastomosis using the Metallic Anastomotic Clip.
  • Procedure: Laparoscopic transit bipartition (gastroenteroanastomosis and entero-enteric anastomosis) use the Metallic Anastomotic Clip and with sleeve gastrectomy — A calibrated sleeve gastrectomy ("gastric sleeve") over a 36F calibration tube and , using stapler loads with staples of variable height. This gastric section starts 7 cm above the pylorus in order to accommodate the 3 cm gastro-ileal compression anastomosis using Metallic Anastomosis Clip (MAC) and leave a distance of 4 cm between the distal corner of the anastomosis and the pylorus. Laparoscopical the cecum and the last ileal loop are identified, and the bowel is retrogradely measured, from the ileocecal valve up to a 300 cm far from it, where the gastro-ileal anastomosis will be made. And than leave a distance of 50 cm from gastroileal compression anastomosis creation entero-enteric compression anastomosis using the Metallic Anastomotic Clip.
  • Procedure: laparoscopic duodenal transit bipartition using the Metallic Anastomotic Clip with circular fundocorporeal gastroplication without gastrectomy — The procedure begans creation circular fundocorporeal gastroplication without gastrectomy. A gastroplication calibrated over a 36F calibration tube using two layer nonabsorbable suture. The mobilisation of great curvature and gastroplication starts 4 above the pylorus. The single 3 cm size duodeno-ileal compression anastomosis by use Metallic Anastomosis Clip (MAC) creation post-pyloric at the first duodenal portion (anterior side).

Primary Outcomes

  • T2DM remission rate (Baseline, 1, 2, 3 year after surgery)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2026-04-30
Completion: 2028-05-30
Eligibility
Age: 18 Years – 65 Years
Sex: ALL
Volunteers: false
Enrollment: 90 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: The Society of Bariatric and Metabolic Surgeons of Kazakhstan
Collaborators: Astana Medical University
Principal Investigators:
  • Oral Ospanov, Professor (PRINCIPAL_INVESTIGATOR) - Astana Medical University
Contact Information
Study Contact:
Oral Ospanov
Astana, Kazakhstan, 010000
bariatric.kz@gmail.com
Bakhtiyar Yelembayev
elembaevbaha@gmail.com
Oral Ospanov
+77015287734
bariatric.kz@gmail.com
Oral Ospanov
Interventions
  • Procedure: Laparoscopic transit bipartition with Metallic Anastomotic Clip and Circular Fundocorporeal Gastroplication — The procedure begans creation circular fundocorporeal gastroplication without gastrectomy. A gastroplication calibrated over a 36F calibration tube using two layer nonabsorbable suture. The mobilisation of great curvature starts 4 cm above the pylorus and gastroplication starts 7 above the pylorus for the creation 3 cm gastro-ileal compression anastomosis using Metallic Anastomosis Clip (MAC) and leave a distance of 4 cm between the distal corner of the anastomosis and the pylorus. Laparoscopical the cecum and the last ileal loop are identified, and the bowel is retrogradely measured, from the ileocecal valve up to a 300 cm far from it, where the gastro-ileal anastomosis will be made. And than leave a distance of 50 cm from gastroileal anastomosis creation entero-enteric compression anastomosis using the Metallic Anastomotic Clip.
  • Procedure: Laparoscopic transit bipartition (gastroenteroanastomosis and entero-enteric anastomosis) use the Metallic Anastomotic Clip and with sleeve gastrectomy — A calibrated sleeve gastrectomy ("gastric sleeve") over a 36F calibration tube and , using stapler loads with staples of variable height. This gastric section starts 7 cm above the pylorus in order to accommodate the 3 cm gastro-ileal compression anastomosis using Metallic Anastomosis Clip (MAC) and leave a distance of 4 cm between the distal corner of the anastomosis and the pylorus. Laparoscopical the cecum and the last ileal loop are identified, and the bowel is retrogradely measured, from the ileocecal valve up to a 300 cm far from it, where the gastro-ileal anastomosis will be made. And than leave a distance of 50 cm from gastroileal compression anastomosis creation entero-enteric compression anastomosis using the Metallic Anastomotic Clip.
  • Procedure: laparoscopic duodenal transit bipartition using the Metallic Anastomotic Clip with circular fundocorporeal gastroplication without gastrectomy — The procedure begans creation circular fundocorporeal gastroplication without gastrectomy. A gastroplication calibrated over a 36F calibration tube using two layer nonabsorbable suture. The mobilisation of great curvature and gastroplication starts 4 above the pylorus. The single 3 cm size duodeno-ileal compression anastomosis by use Metallic Anastomosis Clip (MAC) creation post-pyloric at the first duodenal portion (anterior side).
Study Locations (1 sites)
Oral Ospanov, Astana, 010000 Kazakhstan
Eligibility Criteria
Inclusion Criteria: * Clinical diagnosis of Type 2 Diabetes Mellitus * BMI 25-35 kg/m2 Exclusion Criteria: * Insulin dependent diabetes * BMI \<25 and \>35 kg/m2 * History of surgery on the stomach * Less than 18 or more than 65 years of age * Psychiatric illness * Patients unwilling or unable to provide informed consent
Conditions Diabetes Mellitus Type 2
Phase NA
Enrollment 7792
Locations 12 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-19
Study Details Design, interventions, and primary outcomes

About This Study

This randomized, parallel-group clinical trial evaluates the effectiveness of a continuity of care intervention to improve metabolic control in adults with type 2 diabetes mellitus (T2DM) in the Terres de l'Ebre health region. The intervention, led by the Endocrinology Service at Hospital de Tortosa Verge de la Cinta (HTVC), involves structured, multidisciplinary training and feedback provided by endocrinologists and nurse educators to primary care professionals. Training modules combine theoretical and practical content focused on current diabetes management. Primary care centers are randomized to intervention or control arms. Eligible participants are adult patients with an active diagnosis of T2DM for at least 12 months as of January 2025, registered in the eCAP system. All primary care professionals in intervention centers participate in the training. The intervention is conducted over one year (July 2025-July 2026). Outcomes are assessed at baseline, 6, 12, and 24 months. The primary outcome is HbA1c; secondary outcomes include other health indicators, professional knowledge and engagement, and organizational variables. A qualitative component gathers professional input before and after the intervention to inform future implementation. All data are anonymized to ensure confidentiality.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Other Masking/blinding: Triple

Interventions / Regimen

  • Other: Continuity-of-Care intervention — The intervention is a structured, multidisciplinary training and feedback program led by the Endocrinology Service at HTVC in collaboration with primary care centers in Terres de l'Ebre. Four endocrinologists and four nurses (three educators and one diabetic foot referent) will provide onsite training to primary care physicians and nurses. Training includes six modules with theoretical and practical components, covering T2DM management, cardiovascular risk reduction, and diabetic foot care. Sessions will be held biweekly and delivered by doctor-nurse teams rotating through the participating primary care centers from July 2025 to July 2026, with each center receiving a total of 15 sessions per year. The program also includes regular feedback to professionals on clinical performance and patient outcomes, adapting content to each center's needs. A qualitative component, involving focus groups before and after the intervention, will gather feedback and inform future implementation.

Primary Outcomes

  • HbA1c (At enrollment, 6, 12, and 24 months after enrollment.)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-07-20
Completion: 2027-07-20
Eligibility
Age: 18 Years – 90 Years
Sex: ALL
Volunteers: false
Enrollment: 7792 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Institut Investigacio Sanitaria Pere Virgili
Collaborators: Fundacio d'Investigacio en Atencio Primaria Jordi Gol i Gurina, Institut Catala de Salut
Principal Investigators:
  • Marcela Miret Llauradó, MD (PRINCIPAL_INVESTIGATOR) - Catalan Institute of Health
Contact Information
Study Contact:
Marcela Miret Llauradó, MD
+0034977519100
mmiretl.ebre.ics@gencat.cat
Marcel.la Miret Llauradó
+34-977519100
mmiretl.ebre.ics@gencat.cat
Abs Amposta
Marcel.la Miret Llauradó
+34-977519100
mmiretl.ebre.ics@gencat.cat
Abs Deltebre
Interventions
  • Other: Continuity-of-Care intervention — The intervention is a structured, multidisciplinary training and feedback program led by the Endocrinology Service at HTVC in collaboration with primary care centers in Terres de l'Ebre. Four endocrinologists and four nurses (three educators and one diabetic foot referent) will provide onsite training to primary care physicians and nurses. Training includes six modules with theoretical and practical components, covering T2DM management, cardiovascular risk reduction, and diabetic foot care. Sessions will be held biweekly and delivered by doctor-nurse teams rotating through the participating primary care centers from July 2025 to July 2026, with each center receiving a total of 15 sessions per year. The program also includes regular feedback to professionals on clinical performance and patient outcomes, adapting content to each center's needs. A qualitative component, involving focus groups before and after the intervention, will gather feedback and inform future implementation.
Study Locations (12 sites)
Abs Amposta, Amposta, Tarragona 43870 Spain
Abs Deltebre, Deltebre, Tarragona 43580 Spain
Abs Ametlla-Perelló, El Perelló, Tarragona 43860 Spain
ABS FLIX, Flix, Tarragona 43750 Spain
Abs Gandesa, Gandesa, Tarragona 43780 Spain
Abs Ampolla-Aldea, L'Ampolla, Tarragona 43895 Spain
Abs Mora La Nova, Móra la Nova, Tarragona 43770 Spain
Abs La Ràpita-Alcanar, Sant Carles de la Ràpita, Tarragona 43540 Spain
Abs Tortosa Est, Tortosa, Tarragona 43500 Spain
Abs Tortosa Oest, Tortosa, Tarragona 43500 Spain
Eligibility Criteria
Inclusion Criteria: Enrollment will begin in July 2025, aligned with the initiation of training sessions for healthcare professionals (physicians and nurses). Eligible participants must: * Be adults (≥18 years old) * Have an active diagnosis of T2DM documented in the eCAP primary care electronic health record system * Have a duration of T2DM of at least 12 months as of January 2025 Exclusion Criteria: * Diagnosis of type 1 diabetes mellitus (T1DM) * T2DM managed by a specialist at the time of inclusion * Current treatment with systemic corticosteroids * Active neoplasia (malignancy) * Gestational diabetes * Pregnancy or breastfeeding * Diagnosis of MACA (advanced chronic disease with life expectancy \<1 year) * Complex chronic patients (CCP) * Diagnosis of dementia * Institutionalized patients or those residing in social healthcare facilities * Age over 90 years * Age under 18 years * Severe psychiatric illness (e.g., psychosis, bipolar disorder, major depression) * History of kidney transplant * Undergoing dialysis * History of alcohol or drug abuse